Valion Bio, Inc. (VBIO) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$6.42M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$5.63M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$2.48M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA -$1.68M; Operating income (m); Depreciation and amortization (m).
Complete source-backed ebitda history.
- Available history
- 2022-12-31 to 2025-06-30
- Data captured
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | (m) | -$6.42M | (m) | (m) | (m) | $57.00K* | -$5.28M* | (m) | $2.70M | $3.72M | (m) |
|---|
| 2026-03-31 | Reported | (m) | -$5.63M | (m) | (m) | (m) | $7.00K | -$5.01M | (m) | $1.85M | $3.78M | (m) |
|---|
| 2025-09-30 | Reported | (m) | -$2.48M | (m) | $146.00K | (m) | $10.00K* | -$2.00M* | $291.00K | $858.00K | (m) | (m) |
|---|
| 2025-06-30 | Reported | -$1.68M | (m) | (m) | (m) | -1950.00% | $3.00K* | -$1.83M* | (m) | $655.00K | $1.02M | (m) |
|---|
| 2025-03-31 | Reported | -$1.38M | (m) | (m) | (m) | -1965.71% | $0.00 | -$889.00K | (m) | $335.00K | $1.04M | (m) |
|---|
| 2024-12-31 | Reported | -$298,000.00 | (m) | (m) | (m) | -165.56% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2024-09-30 | Reported | -$1.43M | (m) | (m) | (m) | -1134.92% | (m) | -$1.41M* | $82.00K | $422.00K | (m) | (m) |
|---|
| 2024-06-30 | Reported | -$1.27M | (m) | (m) | (m) | -903.57% | (m) | -$1.29M* | (m) | $302.00K | (m) | (m) |
|---|
| 2024-03-31 | Reported | -$1.48M | (m) | (m) | (m) | -443.11% | (m) | -$1.67M | (m) | $256.00K | (m) | (m) |
|---|
| 2023-12-31 | Reported | -$2.24M | (m) | (m) | (m) | -628.01% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2023-09-30 | Reported | -$1.76M | (m) | (m) | (m) | -623.76% | $0.00* | -$1.87M* | (m) | $337.00K | (m) | (m) |
|---|
| 2023-06-30 | Reported | -$2.12M | (m) | (m) | (m) | -1318.01% | $24.00K* | -$2.44M* | (m) | $468.00K | (m) | (m) |
|---|
| 2023-03-31 | Reported | -$2.11M | (m) | (m) | (m) | -562.23% | $94.00K | -$2.43M | (m) | $490.00K | (m) | (m) |
|---|
| 2022-09-30 | Reported | (m) | -$2.58M | (m) | (m) | (m) | $5.00K* | -$2.77M* | (m) | $399.00K | (m) | (m) |
|---|
| 2022-06-30 | Reported | (m) | -$3.02M | (m) | (m) | (m) | $0.00* | -$1.75M* | (m) | $497.00K | (m) | (m) |
|---|
| 2022-03-31 | Reported | (m) | -$2.24M | (m) | (m) | (m) | $6.00K | -$2.17M | (m) | $401.00K | (m) | (m) |
|---|
| 2021-09-30 | Reported | (m) | -$1.23M | (m) | (m) | (m) | (m) | -$1.64M* | (m) | $175.00K | (m) | (m) |
|---|
| 2021-06-30 | Reported | (m) | -$1.05M | (m) | (m) | (m) | (m) | -$543.00K* | (m) | $192.00K | (m) | (m) |
|---|
| 2021-03-31 | Reported | (m) | -$1.06M | (m) | (m) | (m) | (m) | -$665.00K | (m) | $198.00K | (m) | (m) |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2025-12-31 | Reported | (m) | -$7.90M | (m) | (m) | (m) | $38.00K | -$7.00M | (m) | $3.13M | $4.77M | $0.00 |
|---|
| 2024-12-31 | Reported | -$4.47M | (m) | (m) | (m) | -573.46% | $0.00 | -$5.72M | (m) | $1.31M | $3.16M | $0.00 |
|---|
| 2023-12-31 | Reported | -$8.24M | (m) | (m) | (m) | -700.43% | $118.00K | -$8.51M | (m) | $1.66M | (m) | (m) |
|---|
| 2022-12-31 | Reported | -$10.09M | (m) | (m) | (m) | -548.26% | $11.00K | -$8.92M | (m) | $1.73M | (m) | (m) |
|---|
| 2021-12-31 | Reported | (m) | -$5.63M | (m) | (m) | (m) | (m) | -$5.61M | (m) | $878.00K | (m) | (m) |
|---|